共 19 条
[1]
Inhaled corticosteroids reduce neutrophilic bronchial inflammation in patients with chronic obstructive pulmonary disease. Confalonieri M,Mainardi E,Della P,et al. Thorax . 1998
[2]
Airway hyperresponsiveness, bronchodilator response, allergy and xmoking predict improvement in FEV1 during long term inhaled corticosteroid treatment.Dutch CNSLD Study Group. Kerstjens H,Overbeek S,Schouten J,et al. European Respiratory Journal . 1993
[3]
Short -term treatment with budesonide does not improve hyperresponsiveness to adenosine 5 ’ monophosphate in COPD. Rutgers S. R,Koeter G. H,van der Mark TW,et al. American Journal of Respiratory and Critical Care Medicine . 1998
[4]
Predictors of loss of lung function and mortality in obstructive lung disease. Burrows B. Eru Respir Rev . 1991
[5]
The dffects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease. Hattotuwa K,Gizycki MJ,Ansari TW,et al. American Journal of Respiratory and Critical Care Medicine . 2002
[6]
Multicentre randomized placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Paggiaro PL,Dahle R,Bakran I,et al. The Lancet . 1998
[7]
Cellular and structural bases of chronic obstructive pulmonry disease. Saetta M,Turato G,Maestrelli P,et al. American Journal of Respiratory and Critical Care Medicine . 2001
[8]
Effect of fluticasone propionate on sputum of patients with chronic bronchitis and emphysema. Llewellyn-Jones C,Harria T,Stockley R. American Journal of Respiratory and Critical Care Medicine . 1996
[9]
Long term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomized controlled trial. Vestbo J,Sorensen T,Lange P,et al. The Lancet . 1999
[10]
D Lopez.Alternative propections of mortality and disability by cause 1990 - 2020: Global Burden of Disease Study. Murray C. J. and A. The Lancet . 1997